For generations, the treatment of depression has been built around the removal of suffering — yet for the majority of those who live with it, the deepest wound is not pain but the extinction of joy. A clinical trial published in JAMA Network Open now offers evidence that a 15-session therapy called Positive Affect Treatment, developed by researchers at SMU and UCLA, can restore what conventional approaches have long left untouched: the brain's capacity to anticipate, receive, and learn from reward. In doing so, it challenges a foundational assumption of mental health care — that healing means
SciTechDaily
· May 12, 2026
· health
· 3 min de lectura
High
Verificación: Verificado
New Therapy Targets Brain's Reward System to Restore Joy in Depression
Anhedonia increases suicide risk and prolongs severe depression in millions of patients, making this treatment advancement potentially life-saving.
◉
Health & Medicine
8180 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% coincidencia
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% coincidencia
Cobertura Relacionada
CBS News · Aug 21
Nashville hospital drug mix-up leaves 4 patients with severe complications
Four patients at a Nashville hospital received potassium instead of pain medication during routine joint replacement sur…
BBC News · Aug 21 UK warns vulnerable groups to avoid runny eggs amid salmonella outbreakUK health authorities warn vulnerable populations to avoid undercooked eggs at restaurants due to a rapidly expanding sa…
BBC News · Aug 21 Meghan in talks for Netflix's The Gentlemen as she considers return to actingMeghan is in early talks to return to acting with a role in Netflix's The Gentlemen, marking her first significant actin…
The Pharmaceutical Journal · Aug 21 Survey reveals aesthetic goals driving weight-loss medication use over health concernsA UK survey shows 78% of respondents would consider weight-loss medications for weddings and holidays rather than health…
Impacto Geopolítico
🌎
New psychotherapy (PAT) targets depression's anhedonia symptom; primarily a healthcare/scientific development with no direct geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Sesgo y Encuadre
⚖
Article presents new depression therapy with optimistic framing and limited critical perspective on efficacy claims or potential limitations.
Bias Direction
center-left
Confidence
MED
Promotional framing emphasizing innovation and superiority; positions PAT as breakthrough solution while minimizing discussion of conventional treatments' merits or PAT's limitations.
most disabling symptoms
directly targeting
more effective treatment strategy
restore joy
largely overlooked
breakthrough approach
Critiques or limitations of PAT from independent researchers
Cost-effectiveness analysis compared to conventional treatments
Long-term follow-up data or relapse rates
Perspectives from practitioners of conventional depression therapies
Potential adverse effects or dropout rates
Comparative efficacy data with specific numbers/effect sizes
Accessibility and scalability concerns
Lente Económico
📈
New psychotherapy (PAT) targeting anhedonia shows promise for depression treatment, potentially expanding mental health care market and reducing long-term healthcare costs associated with treatment-resistant depression.
Market Signal
bullish
Confidence
MED
Healthcare/Mental Health Services
Pharmaceutical Industry
Medical Device/Digital Health
Insurance/Health Plans
Behavioral Health Technology
Patients with depression may access more effective treatments, potentially reducing disability, improving workforce productivity, and decreasing suicide-related costs. Could lower out-of-pocket expenses if PAT becomes standard covered therapy versus prolonged medication regimens.
Potential for insurance coverage expansion of psychotherapy-based treatments; regulatory review of PAT efficacy could influence mental health parity laws; may reduce pharmaceutical dependency, affecting drug pricing discussions; workplace mental health policies may evolve to incorporate reward-system-focused interventions.